Compare · head to head
NeoGenomics vs Quest Diagnostics
Quest Diagnostics ranks higher overall — 360 rank 35 vs 31.
Quest Diagnostics leads on Quality (62 vs 35) and Safety (54 vs 23). NeoGenomics leads on Growth (64 vs 46) and Sentiment (62 vs 31). The two are close on Value.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Health Care Providers & Services | Health Care Providers & Services |
| Size | Medium | X-Large |
| ISIN | US64049M2098 | US74834L1008 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 31 | 35 |
| Value | 45 | 42 |
| Quality | 35 | 62 |
| Growth | 64 | 46 |
| Safety | 23 | 54 |
| Sentiment | 62 | 31 |
| Quality details | ||
| Profitability | 23 | 68 |
| Cash Truth | 46 | 56 |
NeoGenomics vs Fulgent GeneticsNeoGenomics vs LabcorpNeoGenomics vs AirSculpt TechnologiesNeoGenomics vs ProgynyAdd a third stock →
Full analyses: NeoGenomics · Quest Diagnostics
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100